Search details
1.
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Adv Ther
; 41(2): 696-715, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38110653
2.
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Adv Ther
; 40(5): 2412-2425, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36961654
3.
Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
Diabetes Ther
; 8(6): 1365-1378, 2017 Dec.
Article
in English
| MEDLINE | ID: mdl-29101681
4.
Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus. / Consumo de recursos sanitarios y costes asociados al inicio del tratamiento con fármacos inyectables en pacientes con diabetes mellitus tipo 2.
Endocrinol Nutr
; 63(10): 527-535, 2016 Dec.
Article
in English, Spanish
| MEDLINE | ID: mdl-27744013
5.
[Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension]. / Eficiencia del inicio con ambrisentan frente a bosentan en el tratamiento de la hipertensión arterial pulmonar.
Farm Hosp
; 37(5): 358-65, 2013.
Article
in Spanish
| MEDLINE | ID: mdl-24128097
6.
[Cost-effectiveness analysis of pneumococcal vaccination in Spain]. / Análisis de coste-efectividad de la vacunación antineumocócica en España.
Gac Sanit
; 25(4): 267-73, 2011.
Article
in Spanish
| MEDLINE | ID: mdl-21640443
7.
Consumo de recursos sanitarios y costes asociados al inicio del tratamiento con fármacos inyectables en pacientes con diabetes mellitus tipo 2 / Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus
Endocrinol. nutr. (Ed. impr.)
; 63(10): 527-535, dic. 2016. tab
Article
in Spanish
| IBECS (Spain) | ID: ibc-158163
8.
Eficiencia del inicio con ambrisentan frente a bosentan en el tratamiento de la hipertensión arterial pulmonar / Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension
Farm. hosp
; 37(5): 358-365, sept.-oct. 2013. ilus, tab
Article
in Spanish
| IBECS (Spain) | ID: ibc-120990
9.
Análisis de coste-efectividad de la vacunación antineumocócica en España / Cost-effectiveness analysis of pneumococcal vaccination in Spain
Gac. sanit. (Barc., Ed. impr.)
; 25(4): 267-273, jul.-ago. 2011. ilus, tab
Article
in Spanish
| IBECS (Spain) | ID: ibc-93229
10.
Impacto sanitario y económico de la vacunación frente al cáncer de cérvix y lesiones precursoras en España / Healthcare and economic impact of vaccination against cervical cancer and precursor lesions in Spain
Prog. obstet. ginecol. (Ed. impr.)
; 55(7): 299-303, ago.-sept. 2012.
Article
in Spanish
| IBECS (Spain) | ID: ibc-102507
Results
1 -
10
de 10
1
Next >
>>